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Abstract
Background: Shared learnings from the early use of novel therapies can aid in their optimization. The recent
introduction of peanut oral immunotherapy (peanut OIT; Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp])
for peanut allergy addresses a significant unmet need but also highlights the requirement for consideration of several
factors by both prescribers and patients.
Objective: To provide guidance for prescribers of licenced peanut OIT to facilitate treatment delivery and improve
outcomes.
Methods: Clinicians with experience of licenced peanut OIT (United States n = 6, United Kingdom n = 1) participated
in a series of interviews and group discussions designed to elicit tips for successful implementation.
Results: Clinicians identified 8 tips that were considered the most relevant, practical, and impactful for prescribers
of Peanut (Arachis hypogaea) Allergen Powder-dnfp: (1) preparing to provide treatment, (2) assessing the medical
indication for treatment and (3) shared decision making, (4) staff education, (5) establishing office processes, (6)
managing patient expectations and using anticipatory guidance, (7) optimising adherence and (8) maintaining
flexibility throughout the treatment process. In addition, a range of supporting materials (e.g., checklists and action
plans) are provided.
Conclusion: The introduction of a novel therapy often requires healthcare providers to modify or adopt practices
to effectively employ the treatment. The provision of guidance based upon early real-world experiences of licenced
peanut OIT may help inform clinical practice and improve treatment outcomes.
Keywords: Oral immunotherapy, Food allergy treatment, Peanut allergy, Peanut oral immunotherapy,
Desensitization, Shared decision making, Allergy immunotherapy, Adherence, Implementation, Education
Introduction
Peanut allergy (PA) is among the most common food
allergies, with a prevalence of approximately 2% in
Western nations [1–5]. The increasing burden of illness
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is substantial and well documented [6–8]. In 2020, the
first treatment for the mitigation of allergic reactions to
peanut was approved by the United States (US) Food
and Drug Administration (FDA) [9], followed shortly by
European Commission (EC) approval [10]. Palforzia®
[Peanut (Arachis hypogaea) Allergen Powder-dnfp;
defatted powder of Arachis hypogaea L., semen
(peanuts); previously known as AR101; Aimmune
Therapeutics, Brisbane, California, USA] is a licenced
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peanut oral immunotherapy (peanut OIT) indicated
for individuals aged 4–17 years with a confirmed PA
diagnosis. Although there are several published reviews
summarizing how to administer food OIT in everyday
practice [11, 12], most allergists have not chosen to
prescribe food OIT to their patients [13]. Several
reasons for low adoption rates have been identified,
including the time commitment and concerns about
Palforzia’s safety [14, 15]. Prescribing licenced peanut
OIT involves introducing a new treatment paradigm
for many prescribers (Fig. 1). Eight tips developed by
early adopters and treatment pioneers are presented,

Fig. 1 Outline of Palforzia protocol

Fig. 2 Tip generation process

Page 2 of 9

highlighting the skills, logistical, and practical
considerations required for implementation. Our goal
is for these learnings to support implementation as
licenced peanut OIT becomes more widely accessible
across the US, the UK and beyond.

Methods
A summary of the methods employed to develop
the tips is presented in Fig. 2. Further details of the
methods are presented in Additional file 1.
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Eight tips for the implementation of licenced
peanut OIT into clinical practice
Eight tips for the implementation of licenced peanut OIT
into clinical practice into the US, the UK and beyond are
outlined below (Table 1).
Tip 1: prepare for providing licenced peanut OIT

Before opting to offer licenced peanut OIT to patients,
the provider should carefully consider the facilities,
staffing, clinical experience, operational processes, time,
and commitment required. In-office administration
of OIT involves resources similar to those needed to
perform an oral food challenge (OFC), including time,
sufficient staff, office space, preparation to treat adverse
events, and possibly hospital proximity [16]. In most
practices, these perceived barriers can be overcome
with proper preparation. Physicians who are already
comfortable and whose office is equipped to conduct
OFCs would be well suited to deliver licenced peanut
OIT. A flowchart summarising the process is presented
in Fig. 3.
Adequate staffing is needed to schedule patients, keep
refrigerated office dose kits stocked, and order patientspecific doses. These include the initial dose escalation
(IDE) card, subsequent up-dosing packs, and a final
maintenance dose pack. The clinical team may involve
other physicians (e.g., 24/7 call coverage), advanced
practice providers to supervise the procedure, and nurses
to prepare and administer doses and assess for reactions.
In contrast to food OIT that is not FDA approved,
with Palforzia there is no need for preparation of the
allergen. Consideration of space and time is needed when
assessing clinical facilities. The IDE takes three hours and
is like an incremental food challenge. The 11 subsequent
up-dosing visits require 60 min for monitoring.
It is also important for clinics administering licenced
peanut OIT to be prepared for emergencies [17],
including a health care provider with experience in
recognizing and treating anaphylaxis and availability

Table 1 Eight Tips for the Implementation of Palforzia into
clinical practice
1. Prepare for providing Palforzia
2. Assess the medical indication for treatment
3. Shared decision making is essential
4. Education is key for staff
5. Establish processes to streamline treatment
6. Manage patient expectations and use anticipatory guidance
7. Optimize adherence
8. Be flexible—it’s a marathon not a sprint
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Is Palforzia right
for your practice?

No

Identify/collaborate with other
groups that could give your
patients Palforzia

Yes
Train staff to give Palforzia
Register for REMS

Identify candidate patients
to receive Palforzia

No
Shared decision making:
Is Palforzia is right for your
patient?

Continued avoidance, carry
epinephrine

Yes

Teach patient and family about OIT:
Identify patient goals and expectations
Patient registers for REMS

Healthplan
Authorization for
Palforzia

No
Appeal denial and reapply

Yes

Proceed with Palforzia Up-Dosing:
Track logistics; schedule up-dose visits
Communicate about adverse reactions, if any
Adjust doses if needed and monitor adherence

Palforzia Maintenance
Continue daily dosing at home with periodic
follow-up visits; Reinforce importance of cofactors, especially exercise restriction after
dosing

Fig.3 Palforzia flow-chart. Figure developed for the US. Modifications
may be required for other countries

of epinephrine and other medications and equipment
needed to treat severe systemic allergic reactions.
Relatedly, providers and healthcare settings should
prepare to follow all necessary precautions to minimize
the risk of anaphylaxis with peanut OIT treatment
as specified in respective licencing information.
Requirements may vary depending on location.
However, in the US, the FDA stipulates that the
prescriber, healthcare setting and patient must enrol in
a mandatory Risk Evaluation and Mitigation (REMS)
program due to risk of a severe systemic allergic
reaction (including anaphylaxis) [9]. The prescribers
complete an attestation of their responsibilities [18],
and the healthcare setting must be equipped to manage
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anaphylaxis and have procedures in place to assure
that patients are monitored during the IDE and each
up-dosing visit. Similarly, in Europe and the UK a
risk-management plan (RMP) was submitted to the
European Medicines Agency (EMA) when Palforzia was
undergoing marketing authorisation assessment. This
plan provides a detailed description of the activities
and interventions designed to identify, characterise,
prevent or minimise risks relating to the medicine. The
Palforzia RMP has a provision that educational risk
minimisation materials must be provided to the health
care professionals and patients caregivers to cover
important safety information [19].
Tip 2: assess the medical indication for treatment

Confirmation of PA is essential before starting treatment.
Diagnosis should be based on a clinical history suggestive
of an IgE mediated reaction to peanut, accompanied by
a positive peanut skin prick test and/or elevated peanut
specific IgE and components [20]. Although it is not
practical or necessary to perform an OFC on all patients
before treatment initiation, a physician-supervised OFC
should be considered if there is uncertainty regarding
PA diagnosis, especially in an individual whose PA
diagnosis is based on testing alone. There are multiple
potential benefits to performing an OFC, including
either confirming or refuting the diagnosis, establishing
a threshold dose for clinical reactivity, and improved
health-related quality of life, regardless of food challenge
outcome [21].
Once a diagnosis is confirmed, additional patientspecific factors should be considered prior to treatment,
including contraindications for OIT such as uncontrolled
asthma or eosinophilic gastrointestinal disorders [9].
Relative contraindications to treatment may include
certain chronic medical conditions (e.g. inflammatory
bowel disease or mast cell disorders) and medications
that may increase the risk of adverse events (e.g. beta
blockers).
A previous history of severe systemic allergic reaction
may be an important reason to pursue treatment with
licenced peanut OIT. Patients with such histories
were included in pivotal trials of Palforzia. However,
individual practices may differ in their comfort level
treating patients with a history of PA reactions involving
significant hypotension or requiring intubation.
Significant skin test reactivity or high levels of peanutspecific IgE are not contraindications to treatment, as
these patients were included in the pivotal trials and their
presence did not accurately predict success or failure
with treatment [22]. Other factors to consider include
details of a patient’s living situation, anxiety, or projected
adherence due to busy schedules, especially a significant
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commitment to after-school extracurricular activities.
Since the characteristics of the ideal individual/family
for treatment remains unknown, careful shared decision
making is critical.
Tip 3: shared decision making is essential

As is the case with most new therapies, no one “right”
answer exists as to whether one should undergo
treatment. Shared decision making helps to balance
risks and expected outcomes with patient preferences
and values. Table 2 lists considerations that should be
addressed during shared decision-making.
Providers should set aside time for a discussion
between the patient, caregivers, and allergist that is not
rushed and that may help the patient feel empowered to
ask questions and engage in dialogue. For some patients
and caregivers, telemedicine may be a useful platform
for this encounter as it is easily accessible, allows for the
involvement of additional caregivers, and can be done
from the comfort of the child’s home. Depending on the
patient’s age, an initial counseling visit with caregivers
alone may be valuable. Providers should consider
formalizing a workflow in which families carefully
consider their options before signing required paperwork
and prior to the pre-treatment visit.
Information offered by the provider should be easy
to understand and available asynchronously. A form
with frequently asked questions could be posted on the
practice website and included with educational materials.
Provider should consider creating or providing a video
for patients to watch either in the office/clinic or on
the practice website. Information should be reviewed
with families regarding adverse events that may occur,
especially gastrointestinal issues including throat itching,
abdominal pain, vomiting, and symptoms consistent with
the development of eosinophilic esophagitis, as well as
the risk for anaphylaxis. A consent form should outline
the above risks involved in the treatment.
Tip 4: education is key for staff

Staff education should ideally be standardized (e.g.
checklist) to ensure that every patient receives the most
important information (Table 3). Training should include
how to identify treatment candidates, discuss goals of
treatment, the pathophysiology of OIT, proper dose
administration and monitoring, management of adverse
reactions, dosing adjustments for missed doses, and how
to advise patients regarding fever/illness, travel, sports,
and other common questions. Providers should consider
creating a frequently asked questions (FAQ) handout
that can be consulted and updated as new questions are
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Table 2 Considerations to address before starting OIT
Review lifestyle

Clarify timing of daily dose

Understand goals

Review options for Mixing

• Competitive sports and other extracurriculars

• May not increase heart rate for any reason including
sports or other activity for 3 hours after dosing every day

• School schedule

• Will need to be carefully monitored by caregiver to
ensure dose is taken daily

• Vacations and travel

• Up-dosing may be delayed by one or more weeks to
accommodate travel or schoolwork

• Caregiver monitoring

• Will need to be carefully monitored by caregiver for any
reaction after every dose

• Transportation

• Legally authorized caregiver should provide
transportation to clinic; adolescents should not attend
alone

• Early morning before school

• May require 5am wakeup

• Immediately following school dismissal

• activity, even when weather is nice

• Dinnertime

• Must remain awake for monitoring for 3 hours after dos

• Bite-safe

• Life-long daily dosing is required to remain bite safe

• Free eat

• Free eating peanut containing foods may be possible
for some but requires a monitored challenge in clinic
before starting as well as careful explanation of risks

• Remission

• No evidence currently exists that OIT induces remission,
i.e. if daily dosing is stopped; protection may be lost

• Yogurt

• Consider other food allergies

• Ice cream

• Consider particular tastes of child

• Guacamole

• Have multiple options available

• Pudding
• Applesauce
• Smoothie
Review risk factors for systemic reactions

• Exercise (or any activity that increases heart
rate)

• Heart rate may not be elevated for 3 hours after each
dose

• NSAID use

• OIT is likely not possible for those on chronic NSAIDS

• Menstruation

• Consider avoiding up-dosing appointments

• Hot showers

• Drinking water throughout the day, particularly on
up-dose days is crucial

• Dehydration

• Each dose should be taken with a meal or substantial
snack

• Empty stomach
Review medications that treat side effects • Second generation H1 blocker
• H2 blocker

• Patient should have at least one of each that is tolerated
• Family should have on hand prior to starting
• Correct dosing should be provided

identified and answered. A system for answering such
questions should be established to ensure consistency.
Tip 5: establish processes to streamline treatment

Providers should consider establishing distinct processes
for scheduling, tracking, and ordering supplies. Space
and staffing should be considered when scheduling each
visit, especially the IDE. Appropriately scheduling IDE
visits at adequately spaced intervals can ensure there will
be adequate space and staff as the number of individuals
on treatment increase over time. It is imperative to allow
for flexibility when scheduling visits for up-dosing, as
patients may need to delay these visits due to illness

or adverse reactions. Practices may find it beneficial
to reserve specific days for licenced peanut OIT, or to
“cohort” patients in groups.
An electronic medical record (EMR) can facilitate
education, scheduling, documentation, and patient
tracking. It may be useful to create OIT-specific
progress note templates, visit type, and flowsheets to
track dosing visits. Patients may also be given a log to
record home dosing, symptoms etc., to review before
each up-dose. Providers should consider implementing
inventory management processes to track Office Dose Kit
inventory, ensure doses are available for scheduled visits,
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Table 3 Checklist of essential components of education
Counselling information
Advise patient, parent, or guardian to read the FDA-approved patient labelling
Advise patient, parent, or guardian that the patient should continue to follow a strict peanut-avoidance diet
Advise patient, parent, or guardian that peanut OIT will not prevent allergic reactions to other foods to which they might
be allergic
Advise patient, parent, or guardian that peanut OIT may cause allergic reactions such as anaphylaxis. Teach them to
recognize the signs and symptoms of anaphylaxis
Patients should have injectable epinephrine and they should be instructed when and how to use it
Inform the patient, parent, or guardian that the first dose of each dose level of peanut OIT must be administered in a
health care setting under the supervision of a health care professional, and that after taking the dose, the patient will be
monitored for signs and symptoms of an allergic reaction
Instruct patient, parent, or guardian that patients with asthma should stop taking peanut OIT and contact their health
care professional immediately if they have difficulty breathing or if their asthma gets worse
The patient should consume the entire prepared mixture
Dosing instructions Advise patient, parent, or guardian
The importance of taking each dose daily to avoid loss of treatment effect
That each dose should be taken with a meal, at approximately the same time each day, preferably in the evening
To observe the patient for at least 60 min after administering peanut OIT for an allergic reaction
To contact their health care professional for advice on how to resume peanut OIT if more than 2 doses are missed
That the risk of an allergic reaction after peanut OIT may be increased in the presence of
• Exercise or exposure to hot water
• A medical illness such as a viral infection
• Not eating for a day
• Sleep deprivation
• Use of nonsteroidal anti-inflammatory drugs such as aspirin or ibuprofen
• Uncontrolled asthma
• Alcohol consumption
If one of these happens, it may be necessary temporarily to withhold or decrease the dose of peanut OIT

and have semisolid food stocked in the office including
choice of applesauce, yogurt, and pudding.
Other considerations such as prior authorization,
insurance approval, and risk minimization programs (e.g.
REMS in the US) will depend on local healthcare setting
and licencing conditions.
Tip 6: manage patient expectations and use anticipatory
guidance

Patients and caregivers must understand that peanut OIT
is not a cure for PA. It is important to communicate to
patients that they should continue to avoid peanut and
to have an epinephrine autoinjector available, even when
the patient reaches the maintenance dose. Finally, it is
important to tell patients that long-term (at least several

years) daily dosing is required to maintain the effect of
treatment.
Patients and caregivers must understand they cannot
‘adjust’ or skip doses on their own, and that all up-dosing
must take place in the office. Transient gastrointestinal
symptoms occur in 85% of children treated with Palforzia
[22]. Anticipatory guidance regarding these likely side
effects (i.e. explaining prior to initiating treatment that
mild allergic side effects indicate the medicine is working)
may reduce patient-related anxiety, increase adherence,
and moderate office call volume. Patients should already
have been trained to use an epinephrine autoinjector and
they should have an anaphylaxis action plan (Additional
file 2). Patient instructions regarding the treatment of
adverse reactions and dose adjustments before initiating
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treatment can decrease the potential for after-hours calls
(Additional file 3).
There should be a plan in place to manage common
side effects. H1 and H2 blockers are routinely used
to manage side effects of OIT [23, 24], and families
should know when to rely on these interventions to
help with chronic symptoms, even if mild. Practices
may also consider providing families with a formal
side effect action plan, similar to an emergency action
plan used to manage accidental ingestions (Additional
file 1). For example, step one may include the initiation
of a second-generation H1 blocker followed by an H2
blocker if symptoms fail to satisfactorily resolve. Step
two may include delaying up-dose visits to monthly
instead of biweekly as is commonly done in clinical
practice when managing patients receiving other
forms of allergen immunotherapy (e.g., aeroallergen
or venom immunotherapy). Other written reminders
may include increasing food intake with the therapeutic
dose and staying hydrated throughout the course of
therapy. Despite best efforts, not all side effects will be
effectively treated or prevented and a clear mechanism
for communication with practice providers 24 h a day,
7 days a week should be provided. Between anticipatory
guidance and access to a practice provider, most patients
and families should be able to successfully navigate the
OIT journey.
Tip 7: optimize adherence

Patient adherence strategies fall into two categories—
managing taste aversion and attenuating co-factors
that potentiate side effects. Patients normally have an
inherent aversion to the taste of peanuts [25]. In addition,
Palforzia contains inactive ingredients that have a distinct
taste that some patients may find unpalatable. These can
lead to discontinuation, missed doses, and, with older
children, hiding doses, creating a false sense of security
for the family—so parental supervision is important.
Providers should be creative with semisolid food, for
example, chocolate flavored foods or strong flavored
foods such as salsa can mask the taste. Mixing with cold
foods, such as ice cream can help. The temperature of
foods can not only mask the taste but can also help with
decreased local symptoms such as oral itching. Drinking
fluids afterwards may also decrease side effects by
reducing deposition on the oral mucosa and esophagus.
Due to taste aversion, side effects, and fear of peanuts,
dosing can lead to a daily stressful event for the family,
thus, finding ways to make it a positive and rewarding
experience is essential.
It is crucial to adhere to a 3-h post-dose exercise
restriction, take doses after a full meal, ensure adequate
hydration, and avoid factors that increase heart rate
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and/or body temperature (e.g., hot showers/bath,
playing physical video games). Other cofactors such as
NSAIDs and alcohol also have the potential to increase
adverse reactions. Parents should monitor the effects
of menstruation, stress, anxiety, and sleep deprivation
and should ensure asthma and allergic rhinitis are well
controlled [26, 27].
Tip 8: be flexible—it’s a marathon, not a sprint

The dosage schedule recommended for licenced
peanut OIT has been extensively tested and generally
is successful, however, it can be modified if needed. As
with other immunotherapies, remaining flexible and
personalizing the therapy to the individual is essential.
Personalizing the dosing and schedule will likely lead to
a lower incidence of allergic reactions and other adverse
events in real-world practice compared to clinical trials.
Allergists are uniquely equipped to handle this dynamic
process given their long-standing experience with
subcutaneous immunotherapy (SCIT).
Moving through up-dosing at a conservative pace
can benefit the practice and the patient [14]. Although
families may be tempted to “sprint” to maintenance
dosing, current evidence does not support this as
desirable or necessary, and prescribing information
allows prescriber discretion, as long as up-dosing
intervals are at least 2 weeks. Unlike SCIT, since patients
are dosing their immunotherapy daily, up-dosing
reactions should not increase if visits are extended;
rather, extending the time interval between up-dosing
visits allows for longer exposure to a given dose level,
which may improve tolerability to the next dose level.
Although improved safety with longer up-dosing
intervals has not been proven, evidence supports that
immunomodulation is ongoing before the maintenance
dose is achieved, even at stable lower doses [22]. Careful
observation of increasing gastrointestinal side effects
including mouth tingling and stomach discomfort
serve as useful guides to delay up-dosing. A child who
experiences a stomachache despite pretreatment with H1
and H2 blockade may benefit from a several-week “pause”
where the same dose is taken at a constant or lower daily
for longer than 2 weeks to allow symptoms to clear
before an attempt is made to up-dose again. Additionally,
a patient may simply prefer, for lifestyle accommodation,
to up-dose monthly or every other month. For example,
patients who are traveling long distances to see a provider
may choose to space out intervals to make travel time
more tolerable, or patients who have difficulty catching
up after missing school may choose to up-dose only on
school holidays.
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Discussion
Recent advances in the treatment of PA have led to the
first FDA and EC-approved treatment for the mitigation
of allergic reactions to peanut. While many children
and adolescents with PA stand to benefit from licenced
peanut OIT, the adoption of any new therapy requires
careful thought about the skills, logistical and practical
considerations required for successful implementation.
This project brought together clinicians from a range of
practice settings, clinicians with and without experience
of OIT for foods other than peanut, and clinicians with
and without experience of Palforzia in clinical trials. All
but one of the clinicians were located in the US, reflecting
the landscape of licenced peanut OIT implementation
at the time of the advisory board. While the inclusion
of prescribers based predominantly in the US may be
considered a limitation, we believe that the majority of
the tips presented are relevant and of value to prescribers
beyond the US and the UK. As Palforzia becomes more
widely available outside of the US, it is important to
consider how the tips presented in this report can be
adapted to be applicable in a range of healthcare settings
and locations. For example, there may be differences in
requirements for prior authorization, insurance approval,
and risk minimization programs. In this manuscript
we do not elaborate on forms of OIT that are not yet
approved by the FDA or EC. For example, some allergists
may elect to offer licenced OIT for PA alongside tree
nuts, egg, and milk for patients with those allergies. Our
intent is not to neglect these other OIT practices, but
rather to complement them with information specific to
licenced peanut OIT while referring interested readers to
prior reviews for descriptions of un-approved forms of
OIT [11, 12].
We hope that these tips will assist a wide range of
potential prescribers to offer licenced peanut OIT. In
addition to benefitting patients and families who have for
so long endured the burden of untreated food allergies,
providing successful OIT treatment in a clinical practice
can be a source of profound professional satisfaction, and
it is our hope that this manuscript will help facilitate the
safe addition of Palforzia into routine allergy practice.
Abbreviations
EMR: Electronic medical record; FDA: Food and Drug Administration; IDE:
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